Nektar Therapeutics Stock Price, News & Analysis

Nektar Therapeutics (NKTR) announced significant findings from two presentations at the 64th ASH Annual Meeting. The first focused on NKTR-255, an investigational IL-15 receptor agonist that enhances NK and CD8+ T cell proliferation, which is set for a Phase 2/3 trial in relapsed/refractory large B-cell lymphoma (LBCL) following CAR-T therapy. The second presentation revealed NKTR-255’s potential to restore NK cell levels after daratumumab treatment in relapsed/refractory multiple myeloma, showing a notable 4-fold expansion of NK cells. The results indicate NKTR-255's promise in augmenting CAR-T efficacy.

Nektar Therapeutics (Nasdaq: NKTR) will host an investor and analyst event on December 12, 2022, at 7:30 a.m. CST. The event will feature management and Dr. Cameron Turtle, Chair of Cancer Immunotherapy at the University of Sydney, discussing the NKTR-255 program and the role of IL-15 in cell therapy. A live webcast will be available at this link, with replay access through January 12, 2023.

Nektar Therapeutics (Nasdaq: NKTR) presented promising preclinical data for NKTR-288 at the 2022 SITC Annual Meeting. NKTR-288, a PEG-conjugate of interferon gamma, demonstrated enhanced anti-tumor activity through upregulation of MHC Class I and PD-L1 in tumors, particularly in combination with anti-PD-1 or anti-PD-L1 therapies. The findings support further clinical evaluation of NKTR-288 as both a monotherapy and in combination treatments. The ongoing Phase 2 JAVELIN Bladder Medley study, led by Merck KGaA, aims to provide comparative efficacy data by end of 2024.

Nektar Therapeutics (Nasdaq: NKTR) has published preclinical data in Blood Advances on its product NKTR-255, a polymer-conjugated human IL-15. The findings show NKTR-255 induces CD8⁺ T cell and natural killer cell proliferation and enhances the efficacy of human CD19 CAR-T cells in lymphoma models. The company plans to progress into a Phase 2/3 clinical trial for NKTR-255 in combination with CAR-T therapies for relapsed or refractory diffuse large B-cell lymphoma. These promising results support ongoing research into NKTR-255's potential in cancer immunotherapy.

Nektar Therapeutics (Nasdaq: NKTR) reported its Q3 2022 financial results, showing a revenue of $23.6 million, down from $24.9 million in Q3 2021. Cash and marketable securities amounted to $546.4 million, supporting operations until mid-2025. Operating costs significantly decreased to $77.9 million from $138.5 million in the same quarter last year, primarily due to a reduction in R&D expenses. Net loss was $59.0 million, improved from $129.7 million year-over-year. The company highlights progress in its oncology and immunology pipeline, including positive data from NKTR-358.

Nektar Therapeutics (Nasdaq: NKTR) will announce its third quarter 2022 financial results on November 3, 2022, following the close of U.S. financial markets. CEO Howard Robin will host a conference call at 5:00 p.m. ET to discuss the results. Investors can access the press release and live audio webcast on the Nektar website, with a replay available until December 3, 2022.

Nektar focuses on oncology, immunology, and inflammatory diseases, boasting a robust R&D pipeline.

Nektar Therapeutics (NKTR) presented data from two Phase 1b studies of rezpegaldesleukin (LY3471851) for treating atopic dermatitis and psoriasis at the 2022 EADV Congress. The studies indicate a favorable safety profile and dose-dependent efficacy in patients with moderate-to-severe atopic dermatitis, with improvements observed up to 36 weeks post-treatment. In psoriasis patients, treatment led to sustained improvements in skin condition metrics. Partnered with Eli Lilly, further Phase 2 studies are planned for 2023, expanding the drug’s potential in addressing autoimmune diseases.

Nektar Therapeutics (Nasdaq: NKTR) announced the publication of preclinical data in Blood Advances on NKTR-255, highlighting its effects on natural killer (NK) cell function in multiple myeloma. The findings demonstrate NKTR-255's ability to enhance NK cell responses, increase NK activating receptor expression, and improve antibody-dependent cellular cytotoxicity (ADCC) in a humanized mouse model. These results support ongoing clinical studies, including a Phase 1 trial for NKTR-255 in relapsed or refractory cancers, showcasing its potential for synergistic treatment effects when combined with other therapies.

Nektar Therapeutics (NKTR) reported Q2 2022 financial results with revenues of $21.6 million, down from $28.3 million in Q2 2021. Operating costs rose to $174.4 million from $138.5 million. The company experienced a net loss of $159.1 million or $0.85 per share, compared to a loss of $125.5 million or $0.69 per share in the prior year. Cash and investments totaled approximately $628.2 million, expected to fund operations into 2025. Nektar is focusing on promising candidates like NKTR-358 and NKTR-255 to enhance shareholder value.